An Antivirulence Approach for Preventing Cryptococcus neoformans from Crossing the Blood-Brain Barrier via Novel Natural Product Inhibitors of a Fungal Metalloprotease.

MBio
Phylicia A AaronAngie Gelli

Abstract

Cryptococcus neoformans (Cn) is the leading cause of fungal meningitis, a deadly disease with limited therapeutic options. Dissemination to the central nervous system hinges on the ability of Cn to breach the blood-brain barrier (BBB) and is considered an attribute of Cn virulence. Targeting virulence instead of growth for antifungal drug development has not been fully exploited despite the benefits of this approach. Mpr1 is a secreted fungal metalloprotease not required for fungal growth, but rather, it functions as a virulence factor by facilitating Cn migration across the BBB. This central role for Mpr1, its extracellular location, and lack of expression in mammalian cells make Mpr1 a high-value target for an antivirulence approach aimed at developing therapeutics for cryptococcal meningitis. To test this notion, we devised a large-scale screen to identify compounds that prohibited Cn from crossing the BBB by selectively blocking Mpr1 proteolytic activity, without inhibiting the growth of Cn A phytochemical natural product-derived library was screened to identify new molecular scaffolds of prototypes unique to a Cn microecosystem. Of the 240 pure natural products examined, 3 lead compounds, abietic acid, diosgenin, and lupin...Continue Reading

References

Oct 9, 2003·Journal of Medical Microbiology·Steven H M ChenAmbrose Y Jong
Feb 1, 2005·The American Journal of Pathology·Caroline CharlierFrançoise Dromer
Sep 6, 2005·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·B B WekslerP O Couraud
Mar 4, 2008·Mycological Research·Walt W LillyAllen C Gathman
Oct 22, 2008·Infection and Immunity·Caroline CharlierFrançoise Dromer
Nov 7, 2009·European Journal of Medicinal Chemistry·Miguel A GonzálezLiliana Betancur-Galvis
Aug 3, 2010·International Journal of Surgery·Rewati Raman Sharma
Aug 20, 2010·Expert Opinion on Therapeutic Patents·Sonia Escaich
Nov 4, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Julia V GeorgievaInge S Zuhorn
Aug 4, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Mark D LindsleyNatteewan Poonwan
Oct 5, 2011·Mycopathologia·Kalliope TsirilakisDavid L Goldman
Mar 16, 2012·The Journal of Biological Chemistry·Ambrose JongSheng-He Huang
Mar 23, 2013·Neuropathology and Applied Neurobiology·Simone C TauberRoland Nau
Jun 22, 2013·The Journal of Antimicrobial Chemotherapy·Angela LoyseThomas S Harrison
Oct 9, 2013·Acta Crystallographica. Section D, Biological Crystallography·Daniel FernándezIrantzu Pallarès
Mar 15, 2014·Nature Reviews. Microbiology·Richard C AllenSam P Brown
Aug 19, 2015·Current Tropical Medicine Reports·Mahsa AbassiJoshua Rhein
Jun 9, 2016·Virulence·Taissa VilaJosé L Lopez-Ribot
Jun 18, 2016·Drug Design, Development and Therapy·John R Brannon, Maria Hadjifrangiskou
Jul 28, 2016·Virulence·Arielle ButtsP David Rogers
Nov 26, 2016·Biochemical Pharmacology·Sonia Campoy, José L Adrio
Nov 26, 2016·Nature Reviews. Neurology·Peter R WilliamsonThomas S Harrison
Jan 25, 2017·Journal of Analytical Methods in Chemistry·Mafalda JesusSamuel Silvestre
Jan 29, 2017·CNS Neuroscience & Therapeutics·Wei FangWan-Qing Liao
Feb 16, 2017·Frontiers in Plant Science·Karen M FrickRhonda C Foley
Feb 23, 2017·Antimicrobial Agents and Chemotherapy·Hua ZhongYan Wang
Mar 25, 2017·Nature Reviews. Drug Discovery·Seth W DickeyMichael Otto
May 10, 2017·The Lancet Infectious Diseases·Radha RajasinghamDavid R Boulware
May 16, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Mark W TenfordeJoseph N Jarvis
Jul 18, 2017·Frontiers in Cellular and Infection Microbiology·Sarisa Na PombejraAngie Gelli

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
Protease Activity assay

Software Mentioned

Prism GraphPad

Related Concepts

Related Feeds

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Central Nervous System Fungal Infections

Central nervous system fungal infections are rare and typically occur in immunocompromised patients, such as those with HIV infection or transplant recipients. Discover the latest research on central nervous system fungal infections here.

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.